Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The 7 major multiple myeloma markets reached a value of US$ 16.4 billion in 2023. The 7MM are forecast to reach US$ 38.1 billion by 2034, exhibiting a growth rate (CAGR) of 9.82% during 2023-2034.
This report provides an exhaustive analysis of the multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.
The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an increasing incidence and mortality of this indication.
Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the multiple myeloma market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the multiple myeloma market
This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs:
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Key Questions Answered in this Report
- How has the multiple myeloma market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
- What is the size of the multiple myeloma patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of multiple myeloma?
- What will be the growth rate of patients across the seven major markets?
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for multiple myeloma drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple myeloma market?
Key Attributes
| Report Attribute | Details |
| No. of Pages | 136 |
| Forecast Period | 2023-2034 |
| Estimated Market Value (USD) in 2023 | $16.4 Billion |
| Forecasted Market Value (USD) by 2034 | $38.1 Billion |
| Compound Annual Growth Rate | 8% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/yc638w
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
